Press Releases

Date	Title
5/10/10	AVI BioPharma Announces First Quarter 2010 Financial Results
5/7/10	AVI BioPharma and Collaborators Publish Data From Preclinical Studies Demonstrating the Antimicrobial Efficacy of PMO Oligomers Against Burkholderia Cepacia Complex in The Journal of Infectious Diseases
5/3/10	AVI BioPharma Announces First Quarter 2010 Financial Results and Corporate Update Conference Call
4/28/10	AVI BioPharma Secures Increased Funding of Approximately $4.0 Million Under Its Contract With the U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu
4/21/10	AVI BioPharma Appoints David Boyle Interim President and CEO
3/26/10	AVI BioPharma Issues Statement Regarding Filing by Shareholder Group
3/25/10	AVI BioPharma Announces Pending Changes to Board of Directors
3/25/10	AVI BioPharma Announces Update on AVI-5038, Its PPMO Duchenne Muscular Dystrophy Drug Candidate, to Be Presented April 14, 2010 at the American Academy of Neurology Annual Meeting
3/16/10	AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
3/9/10	AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call

IR Menu